SCHEDULE: Pentwater Capital Discloses 6% Stake in Blueprint Medicines
Beneficial Ownership Report
Pentwater Capital Management LP and Matthew Halbower have disclosed a 6.0% beneficial ownership stake in Blueprint Medicines Corp., totaling 3.9 million shares.
Summary
- Pentwater Capital Management LP and Matthew Halbower have filed a Schedule 13G, disclosing their beneficial ownership in Blueprint Medicines Corp.
- The reporting persons collectively beneficially own 3,900,000 shares of Blueprint Medicines Corp. Common Stock.
- This ownership represents 6.0% of the total outstanding Common Stock of Blueprint Medicines Corp.
- The percentage is calculated based on 64,733,629 shares of Common Stock outstanding as of June 12, 2025, as reported in the Issuer's Schedule 14D-9.
- The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership, which is inherently neutral. While a significant stake by an investment firm might be viewed positively by the market, the document itself does not convey positive or negative sentiment regarding the company's performance or prospects.
Future Outlook
This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or outlook.
Industry Context
This filing indicates a significant passive investment by a hedge fund in a biotechnology company, which is a common occurrence in the industry as institutional investors seek exposure to growth opportunities in life sciences.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may increase investor confidence and potentially influence trading activity.
- Management: Awareness of a large passive shareholder may influence strategic considerations, though the filing explicitly states no intent to influence control.
Key Dates
| Date | Description |
|---|---|
| 06/12/2025 | Date as of which 64,733,629 shares of Common Stock were outstanding, as reported in the Issuer's Schedule 14D-9. |
| 06/17/2025 | Date the Issuer's Solicitation Statement on Schedule 14D-9 was filed with the SEC. |
| 06/30/2025 | Date of event which requires the filing of this statement. |
| 08/14/2025 | Date the Schedule 13G was signed and filed. |
Keywords
Blueprint Medicines Corp, Pentwater Capital Management, Matthew Halbower, Beneficial Ownership, Schedule 13G, Institutional Investment, Common Stock, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.